Researchers have developed a new tool that will help scientists study how genes are expressed in our cells.
FDA approves GSK’s JAK inhibitor for rare blood cancer after three-month delay
The FDA approved a new JAK inhibitor, momelotinib, from GSK for adults with the rare bone marrow cancer myelofibrosis who also have anemia. The approval
September 16, 2023